01695nas a2200337   4500000000100000008004100001260001300042653002500055653001200080653003200092653002900124653001200153653002400165653003000189653002100219653001100240653001200251653000900263653001800272653002500290653001300315653001700328100001600345700001600361245006000377300001000437490000700447050003200454520085700486022001401343       1980                            d  c1980 Jan10aAlanine Transaminase10aAnimals10aAspartate Aminotransferases10aClinical Trials as Topic10aDapsone10aDouble-Blind Method10aDrug Therapy, Combination10aErythema Nodosum10aHumans10aleprosy10aMice10aMitotic Index10aMycobacterium leprae10aRifampin10aTime Factors1 aGirdhar B K1 aDesikan K V00aIntermittent rifampicin therapy in lepromatous leprosy.  a89-960 v52  aInfolep Library - available3 a<p>A double blind trial involving intermittent administration of Rifampicin in addition to daily DDS has been undertaken in order to evaluate the efficacy as also the potential dangers of such a regimen. Twenty untreated LL cases who were otherwise healthy were included in the study. Ten cases received weekly 900 mg Rifampicin for 6 weeks in addition to 100 mg daily DDS, while the rest were treated likewise but were given similar looking placebo capsules instead of RFP. A nine month follow-up, as also mouse foot pad results indicate that the efficacy of this regimen was found to be better than that with DDS alone and this compares favourably with trials involving 600 mg Rifampician administration daily. No major untoward side effects were encountered in the trial group thought the incidence of ENL was slightly higher in the trial group.</p>  a0024-1024